Designation of Fingolimod (Gilenya, Filosir & Fynefta) as an Orphan drug - Novartis Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves to regulate the quality, safety, and efficacy of therapeutic goods. One of the notable gaps it was introduced to address was the need for incentivising the development of treatments for rare diseases, which typically affect a small number of people. This legislative framework includes provisions for designating orphan drugs, intended to encourage research and development for conditions that might otherwise lack sufficient commercial incentive for pharmaceutical companies. The designation of Fingolimod (GILENYA, FILOSIR & FYNEFTA) as an orphan drug on 24 November 2014, for the treatment of patients with Primary Progressive Multiple Sclerosis (PPMS) by the Delegate of the Secretary, Dr Anthony Gill, is an example of this policy objective in action. This designation aims to facilitate the development and availability of critical treatments for underserved patient groups, ultimately improving health outcomes for those affected by rare conditions.

Scope and Application

The Therapeutic Goods Act 1989, as applied through the Therapeutic Goods Regulations 1990, designates Fingolimod (GILENYA, FILOSIR & FYNEFTA) as an orphan drug for the treatment of patients with Primary Progressive Multiple Sclerosis (PPMS). This designation is specifically for delaying the progression of physical disability and applies to the capsule form of the medication. The Act and its regulations are administered by the Therapeutic Goods Administration, which operates under the Commonwealth of Australia. The designation under Section 16J of the Regulations is applicable nationally and pertains to the sponsor of the medication, in this case, Novartis Pharmaceuticals Australia Pty Ltd. This legislation is pivotal in ensuring that orphan drugs, which are medications intended for rare diseases, receive the necessary support and recognition to facilitate their development and availability. The Act does not detail any exclusions or exemptions in this specific designation but does provide a framework through which broader regulations may be applied or amended to support the therapeutic needs of patients with rare conditions.

Key Provisions

The main operative sections of this gazette concern the designation of Fingolimod as an orphan drug, specifically for the treatment of Primary Progressive Multiple Sclerosis (PPMS). Section 16J of the Therapeutic Goods Regulations 1990 provides the authority to designate a drug as an orphan drug, and under subregulation 16J(2), Dr. Anthony Gill, as the Delegate of the Secretary, has designated Fingolimod for this specific use. This designation acknowledges the drug's importance in treating a rare disease and may provide certain benefits such as priority consideration during the assessment process and potential financial incentives for the sponsor, Novartis Pharmaceuticals Australia Pty Ltd. The designation of Fingolimod as an orphan drug imposes several obligations on the parties involved. Firstly, it mandates that the sponsor, Novartis Pharmaceuticals Australia Pty Ltd, must meet all the requirements set forth by the Therapeutic Goods Administration (TGA) for the drug's approval and ongoing monitoring. This includes providing comprehensive data on the drug's efficacy, safety, and quality. Additionally, the sponsor must comply with any post-market surveillance requirements to ensure the drug's continued safety and efficacy in the patient population. Any breaches of the obligations imposed by this Act can lead to various consequences. Under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990, failure to comply with the requirements for orphan drug designation and marketing approval can result in civil or criminal penalties. For example, if the sponsor fails to provide accurate information or does not comply with post-market surveillance requirements, the TGA can issue infringement notices with penalties up to a certain amount, or in more severe cases, the sponsor may face prosecution leading to fines or imprisonment. The exact penalties depend on the nature and severity of the breach, but they are designed to ensure that therapeutic goods on the market are safe, effective, and of high quality.